| 000 | 01866 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250518082622.0 | ||
| 264 | 0 | _c20210111 | |
| 008 | 202101s 0 0 eng d | ||
| 022 | _a1098-6596 | ||
| 024 | 7 |
_a10.1128/AAC.01921-19 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRossi, Suélen Andreia | |
| 245 | 0 | 0 |
_aIdentification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and _h[electronic resource] |
| 260 |
_bAntimicrobial agents and chemotherapy _c03 2020 |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAmphotericin B _xpharmacology |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntifungal Agents _xpharmacology |
| 650 | 0 | 4 |
_aAuranofin _xpharmacology |
| 650 | 0 | 4 |
_aCandida albicans _xdrug effects |
| 650 | 0 | 4 |
_aCandidiasis _xdrug therapy |
| 650 | 0 | 4 | _aCell Line |
| 650 | 0 | 4 |
_aCiclopirox _xpharmacology |
| 650 | 0 | 4 |
_aCryptococcosis _xdrug therapy |
| 650 | 0 | 4 |
_aCryptococcus neoformans _xdrug effects |
| 650 | 0 | 4 |
_aDrug Evaluation, Preclinical _xmethods |
| 650 | 0 | 4 | _aDrug Repositioning |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 |
_aErythromycin _xpharmacology |
| 650 | 0 | 4 |
_aFlucytosine _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMicrobial Sensitivity Tests |
| 650 | 0 | 4 |
_aOpportunistic Infections _xdrug therapy |
| 650 | 0 | 4 | _aRAW 264.7 Cells |
| 650 | 0 | 4 |
_aZebrafish _xembryology |
| 700 | 1 | _ade Oliveira, Haroldo Cesar | |
| 700 | 1 | _aAgreda-Mellon, Daniel | |
| 700 | 1 | _aLucio, José | |
| 700 | 1 | _aMendes-Giannini, Maria José Soares | |
| 700 | 1 | _aGarcía-Cambero, Jesús Pablo | |
| 700 | 1 | _aZaragoza, Oscar | |
| 773 | 0 |
_tAntimicrobial agents and chemotherapy _gvol. 64 _gno. 4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1128/AAC.01921-19 _zAvailable from publisher's website |
| 999 |
_c30566632 _d30566632 |
||